TAKEDA BEGINS TRIAL OF ACTOS-ARB COMBINATION
Takeda Pharmaceutical has announced that its wholly owned subsidiary, Takeda Global Research & Development Center, has started a Phase III clinical program of fixed-dose combination product Actos (pioglitazone HCl) and Takeda's investigational drug TAK-536 in the U.S.
Actos is being marketed in more than 60 countries, including in the U.S., and is indicated for patients with Type 2 diabetes for improving insulin resistance. TAK-536 is an angiotensin receptor blocker (ARB) currently under development for treatment of hypertension in the U.S. and Europe.
This combined product is expected to provide additional glucose-lowering effects compared with Actos alone, while also offering anti-hypertensive and multi-organ protective action derived from the ARB.